Table 2

Incidence of serious adverse events in TOP*

Event, n (%)n=6148
Patients with ≥1 SAE829 (13.5)
SAEs by SOC and MedDRA preferred term reported in >5 patients*
Infections and infestations254 (4.1)
 PML, confirmed53 (0.9)
 Pneumonia23 (0.4)
 Urinary tract infection20 (0.3)
 Herpes zoster17 (0.3)
 Escherichia urinary tract infection12 (0.2)
 Pyelonephritis10 (0.2)
 Appendicitis8 (0.1)
 Diverticulitis6 (0.1)
 Gastroenteritis6 (0.1)
 Sepsis6 (0.1)
Nervous system†142 (2.3)
 Epilepsy18 (0.3)
 MS15 (0.2)
 Syncope8 (0.1)
 Headache7 (0.1)
 Sciatica6 (0.1)
 Uhthoff’s phenomenon6 (0.1)
Immune system disorders92 (1.5)
 Immune reconstitution inflammatory syndrome‡54 (0.9)
 Hypersensitivity26 (0.4)
Neoplasms benign, malignant and unspecified (including cysts and polyps)88 (1.4)
 Breast cancer12 (0.2)
 Uterine leiomyoma9 (0.1)
Injury, poisoning and procedural complications75 (1.2)
 Fall19 (0.3)
Psychiatric disorders69 (1.1)
 Depression18 (0.3)
 Suicide attempt11 (0.2)
 Completed suicide7 (0.1)
Pregnancy, puerperium and perinatal conditions55 (0.9)
 Abortion spontaneous37 (0.6)
Musculoskeletal and connective tissue disorders48 (0.8)
 Intervertebral disc protrusion12 (0.2)
 Back pain8 (0.1)
Surgical and medical procedures37 (0.6)
 Caesarean section8 (0.1)
General disorders and administration site conditions32 (0.5)
 Fever6 (0.1)
Respiratory, thoracic and mediastinal disorders26 (0.4)
 Pulmonary embolism10 (0.2)
Hepatobiliary disorders24 (0.4)
 Cholelithiasis7 (0.1)
Vascular disorders19 (0.3)
 Deep vein thrombosis6 (0.1)
  • *Each patient was counted only once within each preferred term.

  • †MS relapse was also reported as an SAE in 20 patients (0.3%).

  • ‡One case of immune reconstitution inflammatory syndrome was not associated with PML.

  • MedDRA, Medical Dictionary for Regulatory Activities; MS, multiple sclerosis; PML, progressive multifocal leukoencephalopathy; SAE, serious adverse event; SOC, system organ class; TOP, Tysabri Observational Programme.